These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
318 related articles for article (PubMed ID: 8171432)
1. In vivo phenytoin-initiated oxidative damage to proteins and lipids in murine maternal hepatic and embryonic tissue organelles: potential molecular targets of chemical teratogenesis. Liu L; Wells PG Toxicol Appl Pharmacol; 1994 Apr; 125(2):247-55. PubMed ID: 8171432 [TBL] [Abstract][Full Text] [Related]
2. Potential molecular targets mediating chemical teratogenesis: in vitro peroxidase-catalyzed phenytoin metabolism and oxidative damage to proteins and lipids in murine maternal hepatic microsomes and embryonic 9000g supernatant. Liu L; Wells PG Toxicol Appl Pharmacol; 1995 Sep; 134(1):71-80. PubMed ID: 7676459 [TBL] [Abstract][Full Text] [Related]
3. DNA oxidation as a potential molecular mechanism mediating drug-induced birth defects: phenytoin and structurally related teratogens initiate the formation of 8-hydroxy-2'-deoxyguanosine in vitro and in vivo in murine maternal hepatic and embryonic tissues. Liu L; Wells PG Free Radic Biol Med; 1995 Nov; 19(5):639-48. PubMed ID: 8529923 [TBL] [Abstract][Full Text] [Related]
4. Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity. Parman T; Wiley MJ; Wells PG Nat Med; 1999 May; 5(5):582-5. PubMed ID: 10229238 [TBL] [Abstract][Full Text] [Related]
5. Evidence for embryonic peroxidase-catalyzed bioactivation and glutathione-dependent cytoprotection in phenytoin teratogenicity: modulation by eicosatetraynoic acid and buthionine sulfoximine in murine embryo culture. Miranda AF; Wiley MJ; Wells PG Toxicol Appl Pharmacol; 1994 Feb; 124(2):230-41. PubMed ID: 8122268 [TBL] [Abstract][Full Text] [Related]
6. Oxidative damage in chemical teratogenesis. Wells PG; Kim PM; Laposa RR; Nicol CJ; Parman T; Winn LM Mutat Res; 1997 Dec; 396(1-2):65-78. PubMed ID: 9434860 [TBL] [Abstract][Full Text] [Related]
7. Phenytoin-initiated DNA oxidation in murine embryo culture, and embryo protection by the antioxidative enzymes superoxide dismutase and catalase: evidence for reactive oxygen species-mediated DNA oxidation in the molecular mechanism of phenytoin teratogenicity. Winn LM; Wells PG Mol Pharmacol; 1995 Jul; 48(1):112-20. PubMed ID: 7623765 [TBL] [Abstract][Full Text] [Related]
8. Evidence for lipoxygenase-catalyzed bioactivation of phenytoin to a teratogenic reactive intermediate: in vitro studies using linoleic acid-dependent soybean lipoxygenase, and in vivo studies using pregnant CD-1 mice. Yu WK; Wells PG Toxicol Appl Pharmacol; 1995 Mar; 131(1):1-12. PubMed ID: 7878664 [TBL] [Abstract][Full Text] [Related]
9. In vitro bioactivation of phenytoin to a reactive free radical intermediate by prostaglandin synthetase, horseradish peroxidase, and thyroid peroxidase. Kubow S; Wells PG Mol Pharmacol; 1989 Apr; 35(4):504-11. PubMed ID: 2539558 [TBL] [Abstract][Full Text] [Related]
10. Evidence for embryonic prostaglandin H synthase-catalyzed bioactivation and reactive oxygen species-mediated oxidation of cellular macromolecules in phenytoin and benzo[a]pyrene teratogenesis. Winn LM; Wells PG Free Radic Biol Med; 1997; 22(4):607-21. PubMed ID: 9013124 [TBL] [Abstract][Full Text] [Related]
11. Modulation of phenytoin teratogenicity and embryonic covalent binding by acetylsalicylic acid, caffeic acid, and alpha-phenyl-N-t-butylnitrone: implications for bioactivation by prostaglandin synthetase. Wells PG; Zubovits JT; Wong ST; Molinari LM; Ali S Toxicol Appl Pharmacol; 1989 Feb; 97(2):192-202. PubMed ID: 2493687 [TBL] [Abstract][Full Text] [Related]
13. Reactive oxygen species are involved in lipopolysaccharide-induced intrauterine growth restriction and skeletal development retardation in mice. Xu DX; Chen YH; Zhao L; Wang H; Wei W Am J Obstet Gynecol; 2006 Dec; 195(6):1707-14. PubMed ID: 16769026 [TBL] [Abstract][Full Text] [Related]
14. NTP technical report on the toxicity and metabolism studies of chloral hydrate (CAS No. 302-17-0). Administered by gavage to F344/N rats and B6C3F1 mice. Beland FA Toxic Rep Ser; 1999 Aug; (59):1-66, A1-E7. PubMed ID: 11803702 [TBL] [Abstract][Full Text] [Related]
15. Phenytoin embryotoxicity: role of enzymatic bioactivation in a murine embryo culture model. Shanks MJ; Wiley MJ; Kubow S; Wells PG Teratology; 1989 Oct; 40(4):311-20. PubMed ID: 2814893 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of thalidomide teratogenicity by acetylsalicylic acid: evidence for prostaglandin H synthase-catalyzed bioactivation of thalidomide to a teratogenic reactive intermediate. Arlen RR; Wells PG J Pharmacol Exp Ther; 1996 Jun; 277(3):1649-58. PubMed ID: 8667234 [TBL] [Abstract][Full Text] [Related]
18. The peroxynitrite pathway in development: phenytoin and benzo[a]pyrene embryopathies in inducible nitric oxide synthase knockout mice. Kasapinovic S; McCallum GP; Wiley MJ; Wells PG Free Radic Biol Med; 2004 Dec; 37(11):1703-11. PubMed ID: 15528029 [TBL] [Abstract][Full Text] [Related]
19. UDP-glucuronosyltransferase-mediated protection against in vitro DNA oxidation and micronucleus formation initiated by phenytoin and its embryotoxic metabolite 5-(p-hydroxyphenyl)-5-phenylhydantoin. Kim PM; Winn LM; Parman T; Wells PG J Pharmacol Exp Ther; 1997 Jan; 280(1):200-9. PubMed ID: 8996197 [TBL] [Abstract][Full Text] [Related]
20. Antioxidant and GSH-related enzyme response to a single teratogenic exposure to the anticonvulsant phenytoin: temporospatial evaluation. Amicarelli F; Tiboni GM; Colafarina S; Bonfigli A; Iammarrone E; Miranda M; Di Ilio C Teratology; 2000 Aug; 62(2):100-7. PubMed ID: 10931507 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]